Cooperative Agreement UF1AG046150

This Project Grant award for $564,530.00 was provided by the National Institute on Aging (CFDA 93.866 - Aging Research) to Emory University to investigate the role of the Alzheimer's disease risk gene APOE4 and the hormone follicle-stimulating hormone (FSH) in the development and progression of Alzheimer's disease, particularly in relation to gender-specific differences. The key objectives are to explore how APOE4 and FSH interact to facilitate Alzheimer's pathology, including through tau...

The National Institute on Aging awarded a $2,250,745 Project Grant (CFDA 93.866 - Aging Research) to Mayo Clinic Jacksonville, doing business as Scott Lynch MD, to conduct research on the role of apolipoprotein E (APOE) in meningeal lymphatic function and its impact on Alzheimer's disease pathophysiology. The research aims to uncover the effects of APOE4 expression on meningeal lymphatic drainage and immune cell interactions, and how this may contribute to neuroinflammation and amyloid-β...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $919,106 supports research to discover and optimize "APOE4 correctors" for the treatment of Alzheimer's disease. The award recipient, Sanford Burnham Prebys Medical Discovery Institute, will leverage advanced cellular assays, including a novel split nano-luciferase BITSA, to screen for small molecule compounds that can stabilize the APOE4 protein and make it functionally...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $682,000 will fund research to investigate the influence of microglial cell depletion and repopulation on amyloid-related imaging abnormalities (ARIA) and vascular lesions in individuals with Alzheimer's disease (AD) who carry the APOE4 genetic risk factor. The Roskamp Institute, a non-profit biotechnology research organization, will utilize an EFAD mouse model of AD to characterize...

This Project Grant award from the National Institute on Aging (NIA) under CFDA 93.866 - Aging Research aims to investigate the mechanisms by which the Alzheimer's disease risk factor APOE4 interacts with sex and aging to drive neuronal dysfunction and cognitive decline. The $804,450 award to the J. David Gladstone Institutes will fund a multi-level research effort leveraging advanced techniques like single-nucleus RNA sequencing and in vivo brain activity monitoring. The key objectives are to:...

This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to The Roskamp Institute, Inc. in Sarasota, Florida provides $449,460 in funding to support research investigating the role of cerebrovascular dysfunction and bioenergetic deficits in the increased Alzheimer's disease risk associated with the APOE4 genetic variant. The research aims to determine how APOE4 disrupts L-carnitine-mediated bioenergetic pathways in brain endothelial and mural cells, and...

The National Institute on Aging (NIA) awarded a $341,000 Project Grant (CFDA 93.866 - Aging Research) to The Roskamp Institute, Inc., a non-profit biotechnology research organization in Sarasota, Florida. The grant, effective January 1, 2025 through December 31, 2026, will fund research to investigate the influence of the APOE4 genotype, a major genetic risk factor for Alzheimer's disease, on brain bioenergetics and the cerebrovasculature-astrocyte system. The research aims to examine how...

This Cooperative Agreement award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support Boston University Medical Campus in conducting research to identify genetic and molecular mechanisms underlying the effects of the APOE gene on Alzheimer's disease (AD) risk and progression. The $810,698 award, which runs from September 15, 2024 to June 30, 2029, will enable the researchers to: Leverage large genome-wide association study (GWAS) datasets to discover new APOE...

This $5,274,018 project grant from the National Institute on Aging, part of the Department of Health and Human Services, supports research under the Aging Research program (CFDA 93.866). The J. David Gladstone Institutes will study the susceptibility and resistance to the detrimental effects of the Apolipoprotein E4 (APOE4) genetic risk factor for Alzheimer's disease. The research aims to characterize neurophysiological, behavioral, and neuropathological differences between new APOE4 mouse lines...

This federal Project Grant award, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), is supporting research focused on optimizing and evaluating a brain-permeable CRISPR-based therapy for editing the APOE4 gene associated with Alzheimer's disease (AD). The $751,442 award to the University of California, Los Angeles (UCLA) aims to develop a synthetic exosome (SE)-encapsulated CRISPR system capable of crossing the blood-brain barrier and editing APOE4 to the less...